MI/25/52 Scientific Officer

Key Details

Job ID:
MI/25/52
Role:
Scientific Officer
Salary:
£24,500 – £36,263 dependent upon experience
Closing date:
1st February 2026

About the role

We are currently looking for a Scientific Officer 2 within the Stem Cell Biology group with Prof Georges Lacaud. The aim of this post is to support the on-going research of the group along with the efficient and effective day-to-day running and organisation of the laboratory, to ensure maintenance of equipment and supplies.

The Stem Cell Biology group aims to improve the outcomes of patients suffering from leukaemia by identifying and validating therapeutic targets for treatment and by developing robust protocols for in vitro production of clinical-grade blood cells for adoptive cancer immunotherapies. The specific goal of this work is to unravel the molecular mechanisms of blood cell development using state-of-the-art technologies such as CRISPR screens, proteomics, and multi-omics approaches.

About you

You should have a BSc in Biology or related subject or equivalent relevant experience along with substantial laboratory experience in molecular and cellular biology. Experience working with normal blood cells, flow cytometry, CRISPR, proteomics, genetic engineering and omics is desirable but not essential.

Images created by electron microscope of blood cells from mouse embryonic stem cells in vitro (credit to T.Allen & G.Lacaud).
Paterson Building Scientific Administration

More information

Georges Lacaud

Georges is a Senior Group Leader at the CRUK Manchester Institute where he leads the Stem Cell Biology group. His research focuses on the regulation of normal haematopoiesis to better understand the development of leukaemia and other blood cancers.

Stem Cell Biology

The Stem Cell Biology group are particularly interested in understanding the mechanisms of development and maintenance of leukaemia and identifying and validating new therapeutic targets. Another focus of our work is to uncover the mechanisms of normal haematopoietic development to recapitulate this process in vitro for the generation of therapeutic immune cells.

Cytotoxic therapy has been the standard of care over the last 30 years for acute myeloid leukaemias (AMLs). Unfortunately, more often than not, it fails to cure patients, and the five years survival rate is only around 20%. Therefore, there is a pressing need to develop more specific and efficient therapies.

To this end, our laboratory undertakes two integrated research programmes: a) investigating mechanisms driving initiation and maintenance of leukaemia; and b) extending the understanding of normal haematopoietic system development. Our overarching goals are to improve patient outcomes by identifying and validating new therapeutic targets for leukaemia treatment and developing robust protocols for in vitro production of clinical-grade blood cells for adoptive cancer immunotherapies.

We aim to identify and validate new therapeutic targets in acute myeloid leukaemia. We are implementing advanced technologies, including single-cell multi-omics, CRISPR screening, mass spectrometry, bioinformatics, mouse models, organoid cultures and patient-derived samples analyses in these studies. We also aim to improve our understanding of blood cell development in order to better replicate this process in vitro to generate cells for adaptive cellular immunotherapies. Currently, our incomplete understanding of normal in vivo haematopoietic ontogeny limits our capacity to efficiently replicate this process in vitro. The complexity of haematopoietic development has to be comprehensively defined, and the underlying regulatory mechanisms understood to establish effective in vitro protocols that drive differentiation towards specific haematopoietic lineages.

About CRUK Manchester Institute

Our aim is to understand the fundamental basis of cancer and apply that knowledge to developing new treatment strategies for cancer patients. Our advanced research programmes span a spectrum of cancer research, from the molecular and cellular basis of cancer through to drug discovery, translational research and clinical trials. rnThe Institute has access to outstanding laboratory facilities and exceptional core services, including next generation sequencing, microarrays, confocal microscopy, bioinformatics, histology and mass-spectrometry.

Georges Lacaud
Stem Cell Biology
About CRUK Manchester Institute

How to apply

To apply for this position please complete the online application via ‘Apply Now’. Please ensure you detail the names of two referees and ensure you submit your application before the closing date specified.

For any informal enquiries about this post, please contact Prof Georges Lacaud:  georges.lacaud@cruk.manchester.ac.uk

Please note this vacancy will close for applications at 11:59 pm on the closing date specified.

Closing date: Sunday 01 February 2026.

Contact us for further information

Enter your full name
Enter your email address
Type your question here

Why choose Cancer Research UK Manchester Institute?

The Cancer Research UK Manchester Institute, an Institute of The University of Manchester, is a world-leading centre for excellence in cancer research. The Institute is core funded by Cancer Research UK (www.cancerresearchuk.org),
the largest independent cancer research organisation in the world.

We are partnered with The Christie NHS Foundation Trust, one of the largest cancer treatment centres in Europe, which is located adjacent to the CRUK MI Manchester Institute in South Manchester. These factors combine to provide an exceptional environment in which to pursue basic, translational and clinical research programmes.

Careers that have a lasting impact on cancer research and patient care

We are always on the lookout for talented and motivated people to join us.  Whether your background is in biological or chemical sciences, mathematics or finance, computer science or logistics, use the links below to see roles across the Institute in our core facilities, operations teams, research groups, and studentships within our exceptional graduate programme.

Gloved hands filling a stripette white lab coat

Latest from CRUK MI

Cancer Research In the Paterson Building

Find out more about the facilities across the Institute

Leukaemia Immunology & Transplantation

The Leukaemia Immunology and Transplantation laboratory aim to develop a comprehensive strategy to prevent post-transplant relapse in patients treated with allogeneic haematopoietic stem cell transplantation – the only curative therapy for many patients with acute myeloid leukaemia (AML) and other poor-risk haematological malignancies.

Patient derived preclinical models reveal novel biology of SCLC

Immune detection of dying tumour cells can elicit cancer immunity when the host permits it

Cancer Research In the Paterson Building
Leukaemia Immunology & Transplantation
Patient derived preclinical models reveal novel biology of SCLC